Clinical Trials
Eli Lilly and Company in Collaboration with Strateos Launch Remote-Controlled Robotic Cloud Lab
Eli Lilly and Company and Strateos, Inc. unveiled a new robotic laboratory in San Diego, California designed to accelerate the drug discovery process. The Lilly Life Sciences Studio lab was conceptualized and designed by Lilly as part of a...
Clinical Trials
Moderna Announces Additional Positive Phase 1 Data from CMV Vaccine and First Participant Dosed in Phase 2 Study
Moderna, Inc., a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced positive seven-month interim safety and immunogenicity data after the third and final vaccination in...
Drug Research
Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases
Boehringer Ingelheim and Enleofen Bio Pte. Ltd. (Enleofen) announced the acquisition of worldwide exclusive rights to Enleofen’s preclinical interleukin-11 (IL-11) platform by Boehringer Ingelheim to develop first-in-class therapies across a broad range of fibro-inflammatory diseases.
The new partnership combines Boehringer...
Drug Research
BI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac Meets Primary and Secondary Endpoints
VBI Vaccines Inc. (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported top-line data from CONSTANT, the second pivotal Phase 3 study, assessing lot-to-lot manufacturing consistency of Sci-B-Vac®, the company’s trivalent hepatitis B (HBV) vaccine,...
Drug Research
Generation Bio Announces $110 Million Series C Financing to Advance Lead Programs for Hemophilia A and PKU
Generation Bio, a company leading a new generation of gene therapy, announced the closing of a $110 million Series C financing. Proceeds will be used to advance the company’s two lead liver-targeted programs for hemophilia A and phenylketonuria (PKU)...
News
RenaSci bolsters kidney disease and fibrosis capabilities with senior appointment
Leading in vivo pharmacology and consultancy services firm RenaSci, part of the Sygnature Group, have bolstered their Kidney Disease and Fibrosis capabilities with the appointment of Dr Wioletta Pijacka. Wioletta is an in vivo translational biologist with over 12...
News
Catalent Completes Purchase of Biologics Fill-Finish and Oral Solid Dose Facility in Anagni, Italy
Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, announced the completion of the purchase of Bristol-Myers Squibb’s biologics, sterile, and oral solid dose product manufacturing...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.